Thank you very much.
I'm here representing Genome Prairie, which coordinates and oversees research and development projects that are led by researchers and developers based here in Manitoba and in Saskatchewan, but also includes collaborators throughout Canada and in several other countries.
I want to touch on five main topics that are covered in our brief submission.
The first is that revolutionary scientific and technological advances have given us the ability to determine the genetic makeup, what we call the genome, of plants and animals and to understand how that leads to the physical and biochemical characteristics of individual plants and animals. These discoveries have already led to huge social and economic benefits in human and animal health, in agriculture, forestry, fisheries, energy, and the environment. The pace of development in this area, and our practical application of results, is accelerating very rapidly, and competition to reap the benefits of these advances is intensifying. The first point is that if we want to share fully in those benefits, we need to do more, we need to do better, and we need to do them soon.
The second point is this. Until a decade ago, Canada was largely a bystander in the world of genomic sciences. With the advent of genome centres such as Genome Prairie and a variety of other initiatives, Canada is now a recognized player in genomics research, but we're not realizing our full potential in applying discovery to the development of products and services of social and economic value. We see the goal for policy-makers as twofold. We need to keep the genomics research engine adequately fueled, and we need to effectively link the output of that engine to industrial innovation and thereby to economic growth and social benefit. We have to pursue both of those goals together or we will achieve neither.
The strategies for successfully achieving that dual objective are pretty clear to us. They are, first of all, the need to create or reinforce incentives and also to remove or ameliorate barriers.
On the incentive front--it's my third point--we are fortunate in Canada. We do have some experience and policy tools already in place to build on. We're good at building networks and coordinating agencies that bring essential elements together to foster synergy among governments, academia, and industry. However, these networks and agencies need significantly more funding capacity to initiate and sustain internationally competitive, large-scale projects in genomics-based research, in development, and in commercialization, and to attract correspondingly enhanced investment and commitment by industry.
Fourth, on the element of creating incentives, certain not-for-profit organizations support activities focused directly on the critical challenge of taking discoveries out of the laboratory through the early stages of the development to commercialization. However, these organizations are disadvantaged by being excluded from government initiatives designed to foster research and development, such as Canada's program of scientific research and experimental development credits, so-called SR and ED credits. If refundable SR and ED credits were made available to these not-for-profit organizations, the bench-to-shelf phase—going from the bench to a prototype and to a product that can be marketed—will be significantly strengthened.
Fifth, when it comes to removing or ameliorating barriers, the list of challenges is long. It includes regulatory complexity, market barriers, and scarcity of venture capital. An example drawn from agriculture is the unwillingness of some producers and investors to pursue the potential to enhance certain crop varieties because of the high cost they face in navigating the complex and time-consuming regulatory process. We believe there are clear opportunities to simplify or streamline the regulatory process without in any way compromising quality or safety, so it becomes cost effective for producers and investors to develop new marketable products in these areas.
Let me conclude by saying that we at Genome Prairie are passionate about the mission of fostering the use of genomic tools to address regional, national, and global challenges related to energy shortage, climate change, environmental sustainability, and of course to build and sustain a competitive advantage for Canada in genomics-based industrial innovation in selected fields of agriculture, health, energy, and the environment.
To succeed, we and other similar organizations need responsive, evidence-based public policy backed by increased strategic government investment and the use of the convening power of government to force strong competitive intersectoral partnerships, that is, between academia, government, and industry.
Thank you for your attention.